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Preventing vasospasm improves outcome after aneurysmal
subarachnoid hemorrhage: rationale and design of
CONSCIOUS-2 and CONSCIOUS-3 trials
Abstract
Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) is a frequent but unpredictable
complication associated with poor outcome. Current vasospasm therapies are suboptimal; new therapies
are needed. Clazosentan, an endothelin receptor antagonist, has shown promise in phase 2 studies, and
two randomized, double-blind, placebo-controlled phase 3 trials (CONSCIOUS-2 and CONSCIOUS-3)
are underway to further investigate its impact on vasospasm-related outcome after aSAH. Here we
describe the design of these studies, which was challenging with respect to defining endpoints and
standardizing endpoint interpretation and patient care. Main inclusion criteria are: age 18-75 years; SAH
due to ruptured saccular aneurysm secured by surgical clipping (CONSCIOUS-2) or endovascular
coiling (CONSCIOUS-3); substantial subarachnoid clot; and World Federation of Neurosurgical
Societies grades I-IV prior to aneurysm-securing procedure. In CONSCIOUS-2, patients are randomized
2:1 to clazosentan (5mg/h) or placebo. In CONSCIOUS-3, patients are randomized 1:1:1 to clazosentan
5mg/h, 15mg/h or placebo. Treatment is initiated within 56 h of aSAH and continued until 14 days after
aSAH. Primary endpoint is a composite of mortality and vasospasm-related morbidity within 6 weeks of
aSAH (all-cause mortality, vasospasm-related new cerebral infarction, vasospasm-related delayed
ischemic neurological deficit, neurological signs or symptoms in the presence of angiographic
vasospasm leading to rescue therapy initiation). Main secondary endpoint is extended Glasgow
Outcome Scale (GOSE) at week 12. A critical events committee assesses all data centrally to ensure
consistency in interpretation, and patient management guidelines are used to standardize care. Results
are expected at the end of 2010 and 2011 for CONSCIOUS-2 and CONSCIOUS-3, respectively. 
Introduction Advances have been made in the management of patients with aneurysmal subarachnoid
hemorrhage (aSAH). Mortality among those who reach hospital alive has decreased 0.9% per year since
1980 [1]. Nevertheless, case fatality is still 40% and half of all survivors suffer some form of physical,
emotional or cognitive impairment [2-4]. The causes of morbidity and mortality are mainly initial
effects of the aSAH and delayed ischemic neurological deficit (DIND), which is usually due to cerebral
vasospasm [5]. Indeed, vasospasm is considered to be one of the main preventable causes of morbidity
and mortality [6]. Angiographic vasospasm (vasospasm that is visible on an angiogram) occurs in up to
70% of patients after aSAH [6]; DIND has been estimated to account for 50% of deaths in people
surviving the initial SAH [7].  Current management options for the prevention and treatment of
vasospasm and DIND include hemodynamic therapy, nimodipine, fasudil (in Japan), intra-arterial
vasodilators and angioplasty, but none are very effective [7-12]. Clazosentan is an endothelin receptor
antagonist under investigation for the prevention of vasospasm and subsequent morbidity and mortality.
A phase 2a proof-of-principle trial administered 0.2 mg/kg/h clazosentan (corresponding to 15 mg/h for
an individual weighing 75 kg) beginning within 48 h of the aneurysm securing procedure and continuing
until Day 14 after aSAH. Clazosentan reduced moderate/severe angiographic vasospasm by 55%
relative to placebo (angiographic vasospasm was observed in 88% and 40% of placebo- and
clazosentan-treated patients, respectively, P = 0.008) [13]. These results supported conduct of a
dose-finding safety trial (Clazosentan to Overcome Neurological iSChemia and Infarct OccUrring after
Subarachnoid hemorrhage CONSCIOUS-1; phase 2b]). The primary outcome was angiographic
vasospasm. The sample size was estimated from the effect on angiographic vasospasm in the phase 2a
trial and the doses selected based on the phase 2a trial and also phase 1 clinical trials administering
clazosentan to healthy volunteers and observing clinical and cardiovascular effects [13,14].
CONSCIOUS-1 recruited 413 patients from 11 countries [15]. Patients were randomized to intravenous
clazosentan (1, 5 or 15 mg/h) or placebo, beginning within 56 h of aSAH and continuing until Day 14
after aneurysm rupture. Clazosentan significantly and dose-dependently reduced moderate/severe
angiographic vasospasm relative to placebo; the highest dose (15 mg/h) led to a 65% risk reduction (P <
0.0001) [15]. CONSCIOUS-1 was not powered to detect a change in morbidity, mortality or
patient-centered clinical outcome, but has been repeatedly and incorrectly cited as evidence that
angiographic vasospasm does not contribute to poor outcome after aSAH [16]. This idea was put forth at
least 35 years ago, but the basis remains as speculative now as it was then [17]. Post hoc, central
analysis of all-cause mortality and vasospasm-related morbidity in CONSCIOUS-1 found a trend
towards improved outcomes with clazosentan [15].  Two large, multinational phase 3 studies,
CONSCIOUS-2 and CONSCIOUS-3, have now been initiated, based on the results of the
CONSCIOUS-1 trial, to further investigate the effect of clazosentan on outcome after aSAH. This
manuscript describes the rationale for the design and methodology of these studies. Methods Study
design CONSCIOUS-2 and CONSCIOUS-3 are prospective, multinational, double-blind,
placebo-controlled studies. The primary objective is to determine if clazosentan decreases
vasospasm-related morbidity and all-cause mortality in patients with aSAH. Patients are randomized
within 56 h of aSAH to intravenous clazosentan (5 mg/h in CONSCIOUS-2; 5 or 15 mg/h in
CONSCIOUS-3) or placebo administered until Day 14 after aSAH, with a post-aSAH follow-up period
of up to 12 weeks (Figure 1). Randomization is by an independent contract research organization using
an interactive web response system, which assigns a randomization number according to a predefined
randomization scheme. Randomization is stratified by site.  In both studies, patients are managed
according to procedures for aSAH at the study center (i.e., study drug is added to usual care) although
patient management guidelines have been implemented (see below) to standardize care between centers.
Drugs or procedures that are not standard care are forbidden including intravenous magnesium or statins
when prescribed for the prevention of cerebral vasospasm, thrombolytics and antifibrinolytics,
hypertonic saline without hyponatremia or increased intracranial pressure, calcineurin inhibitors, and
endothelin receptor antagonists other than the study drug. Oral nimodipine is permitted, but not
intravenous nimodipine or intravenous nicardipine. The study protocols are approved by local
institutional review boards. The trials are registered on clinicaltrials.gov: registration numbers:
NCT00558311 (CONSCIOUS-2) and NCT00940095 (CONSCIOUS-3). CONSCIOUS-2 enrolled 1157
patients in 102 centers in 27 countries; CONSCIOUS-3 is expected to enroll more than 1400 patients in
approximately 150 centers in more than 25 countries. The rationale for separate studies of clipped and
coiled patients was based on CONSCIOUS-1 analyses, indicating differences in endpoint occurrence
when patients were stratified by securing procedure. Specifically, in CONSCIOUS-1 patients secured by
clipping, the incidence of the composite endpoint in the placebo group was 45% compared with 46%,
25% and 40% in 1 mg/h, 5 mg/h and 15 mg/h groups, respectively. In contrast, in patients secured by
coiling, the incidence of the composite endpoint in the placebo group was lower at 34% compared with
31%, 32% and 20% in 1 mg/h, 5 mg/h and 15 mg/h groups, respectively. Furthermore, an exploratory,
retrospective analysis of CONSCIOUS-1 data showed that, relative to coiled patients, clipped patients
had significantly higher rates of angiographic vasospasm (36% vs. 55%, respectively) and DIND (15%
and 23%, respectively) [18]. Together these observations supported the conduct of separate trials for
clipped and coiled patients and suggested that while the 5 mg/h dose might be most appropriate for
clipped patients a potentially higher dose was additionally worth investigating in coiled patients. 
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Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) is a frequent but 
unpredictable complication associated with poor outcome. Current vasospasm therapies are 
suboptimal; new therapies are needed. Clazosentan, an endothelin receptor antagonist, has 
shown promise in phase 2 studies, and two randomized, double-blind, placebo-controlled 
phase 3 trials (CONSCIOUS-2 and CONSCIOUS-3) are underway to further investigate its 
impact on vasospasm-related outcome after aSAH. Here we describe the design of these 
studies, which was challenging with respect to defining endpoints and standardizing 
endpoint interpretation and patient care. Main inclusion criteria are: age 18–75 years; SAH 
due to ruptured saccular aneurysm secured by surgical clipping (CONSCIOUS-2) or 
endovascular coiling (CONSCIOUS-3); substantial subarachnoid clot; and World Federation 
of Neurosurgical Societies grades I-IV prior to aneurysm-securing procedure. In 
CONSCIOUS-2, patients are randomized 2:1 to clazosentan (5mg/h) or placebo. In 
CONSCIOUS-3, patients are randomized 1:1:1 to clazosentan 5mg/h, 15mg/h or placebo. 
Treatment is initiated within 56 h of aSAH and continued until 14 days after aSAH. Primary 
endpoint is a composite of mortality and vasospasm-related morbidity within 6 weeks of 
aSAH (all-cause mortality, vasospasm-related new cerebral infarction, vasospasm-related 
delayed ischemic neurological deficit, neurological signs or symptoms in the presence of 
angiographic vasospasm leading to rescue therapy initiation). Main secondary endpoint is 
extended Glasgow Outcome Scale (GOSE) at week 12. A critical events committee 
assesses all data centrally to ensure consistency in interpretation, and patient management 
guidelines are used to standardize care. Results are expected at the end of 2010 and 2011 






Advances have been made in the management of patients with aneurysmal subarachnoid 
hemorrhage (aSAH). Mortality among those who reach hospital alive has decreased 0.9% 
per year since 1980 [1]. Nevertheless, case fatality is still 40% and half of all survivors suffer 
some form of physical, emotional or cognitive impairment [2–4]. The causes of morbidity and 
mortality are mainly initial effects of the aSAH and delayed ischemic neurological deficit 
(DIND), which is usually due to cerebral vasospasm [5]. Indeed, vasospasm is considered to 
be one of the main preventable causes of morbidity and mortality [6]. Angiographic 
vasospasm (vasospasm that is visible on an angiogram) occurs in up to 70% of patients 
after aSAH [6]; DIND has been estimated to account for 50% of deaths in people surviving 
the initial SAH [7].  
Current management options for the prevention and treatment of vasospasm and DIND 
include hemodynamic therapy, nimodipine, fasudil (in Japan), intra-arterial vasodilators and 
angioplasty, but none are very effective [7–12]. Clazosentan is an endothelin receptor 
antagonist under investigation for the prevention of vasospasm and subsequent morbidity 
and mortality. A phase 2a proof-of-principle trial administered 0.2 mg/kg/h clazosentan 
(corresponding to 15 mg/h for an individual weighing 75 kg) beginning within 48 h of the 
aneurysm securing procedure and continuing until Day 14 after aSAH. Clazosentan reduced 
moderate/severe angiographic vasospasm by 55% relative to placebo (angiographic 
vasospasm was observed in 88% and 40% of placebo- and clazosentan-treated patients, 
respectively, P = 0.008) [13]. 
These results supported conduct of a dose-finding safety trial (Clazosentan to Overcome 
Neurological iSChemia and Infarct OccUrring after Subarachnoid hemorrhage CONSCIOUS-
1; phase 2b]). The primary outcome was angiographic vasospasm. The sample size was 
estimated from the effect on angiographic vasospasm in the phase 2a trial and the doses 
selected based on the phase 2a trial and also phase 1 clinical trials administering 
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clazosentan to healthy volunteers and observing clinical and cardiovascular effects [13,14]. 
CONSCIOUS-1 recruited 413 patients from 11 countries [15]. Patients were randomized to 
intravenous clazosentan (1, 5 or 15 mg/h) or placebo, beginning within 56 h of aSAH and 
continuing until Day 14 after aneurysm rupture. Clazosentan significantly and dose-
dependently reduced moderate/severe angiographic vasospasm relative to placebo; the 
highest dose (15 mg/h) led to a 65% risk reduction (P < 0.0001) [15]. CONSCIOUS-1 was 
not powered to detect a change in morbidity, mortality or patient-centered clinical outcome, 
but has been repeatedly and incorrectly cited as evidence that angiographic vasospasm 
does not contribute to poor outcome after aSAH [16]. This idea was put forth at least 35 
years ago, but the basis remains as speculative now as it was then [17]. Post hoc, central 
analysis of all-cause mortality and vasospasm-related morbidity in CONSCIOUS-1 found a 
trend towards improved outcomes with clazosentan [15].  
Two large, multinational phase 3 studies, CONSCIOUS-2 and CONSCIOUS-3, have now 
been initiated, based on the results of the CONSCIOUS-1 trial, to further investigate the 
effect of clazosentan on outcome after aSAH. This manuscript describes the rationale for the 
design and methodology of these studies. 
Methods 
Study design 
CONSCIOUS-2 and CONSCIOUS-3 are prospective, multinational, double-blind, placebo-
controlled studies. The primary objective is to determine if clazosentan decreases 
vasospasm-related morbidity and all-cause mortality in patients with aSAH. Patients are 
randomized within 56 h of aSAH to intravenous clazosentan (5 mg/h in CONSCIOUS-2; 5 or 
15 mg/h in CONSCIOUS-3) or placebo administered until Day 14 after aSAH, with a post-
aSAH follow-up period of up to 12 weeks (Figure 1). Randomization is by an independent 
contract research organization using an interactive web response system, which assigns a 
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randomization number according to a predefined randomization scheme. Randomization is 
stratified by site.  
In both studies, patients are managed according to procedures for aSAH at the study center 
(i.e., study drug is added to usual care) although patient management guidelines have been 
implemented (see below) to standardize care between centers. Drugs or procedures that are 
not standard care are forbidden including intravenous magnesium or statins when prescribed 
for the prevention of cerebral vasospasm, thrombolytics and antifibrinolytics, hypertonic 
saline without hyponatremia or increased intracranial pressure, calcineurin inhibitors, and 
endothelin receptor antagonists other than the study drug. Oral nimodipine is permitted, but 
not intravenous nimodipine or intravenous nicardipine. The study protocols are approved by 
local institutional review boards. The trials are registered on clinicaltrials.gov: registration 
numbers: NCT00558311 (CONSCIOUS-2) and NCT00940095 (CONSCIOUS-3). 
CONSCIOUS-2 enrolled 1157 patients in 102 centers in 27 countries; CONSCIOUS-3 is 
expected to enroll more than 1400 patients in approximately 150 centers in more than 25 
countries. 
The rationale for separate studies of clipped and coiled patients was based on 
CONSCIOUS-1 analyses, indicating differences in endpoint occurrence when patients were 
stratified by securing procedure. Specifically, in CONSCIOUS-1 patients secured by clipping, 
the incidence of the composite endpoint in the placebo group was 45% compared with 46%, 
25% and 40% in 1 mg/h, 5 mg/h and 15 mg/h groups, respectively. In contrast, in patients 
secured by coiling, the incidence of the composite endpoint in the placebo group was lower 
at 34% compared with 31%, 32% and 20% in 1 mg/h, 5 mg/h and 15 mg/h groups, 
respectively. Furthermore, an exploratory, retrospective analysis of CONSCIOUS-1 data 
showed that, relative to coiled patients, clipped patients had significantly higher rates of 
angiographic vasospasm (36% vs. 55%, respectively) and DIND (15% and 23%, 
respectively) [18]. Together these observations supported the conduct of separate trials for 
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clipped and coiled patients and suggested that while the 5 mg/h dose might be most 
appropriate for clipped patients a potentially higher dose was additionally worth investigating 
in coiled patients. 
 
Patient population 
Inclusion and exclusion criteria were selected to enrich the population for vasospasm and to 
exclude patients with poor prognosis who have high mortality before the development of 
vasospasm. Inclusion criteria are: age 18–75 years, SAH due to ruptured saccular 
aneurysm, and World Federation of Neurological Societies (WFNS) grades I–IV prior to 
securing procedure (WFNS grade V patients are excluded due to high early mortality rate). 
Exclusion criteria include SAH due to non-aneurysmal causes, intraventricular or 
intracerebral hemorrhage without subarachnoid blood, the presence of vasospasm on 
screening angiogram and major complications during the aneurysm-securing procedure. 
Entry into CONSCIOUS-2 requires a diffuse clot on the admission computed tomographic 
(CT) scan (long axis ≥ 20 mm or present in both hemispheres) and an aneurysm secured 
through surgical clipping. CONSCIOUS-3 requires a thick clot (short axis ≥ 4 mm) and an 
aneurysm secured by endovascular coiling. This requirement for a large or thick clot 
excludes patients with minimal subarachnoid blood, who are less likely to experience 
vasospasm. In both studies, randomization occurred after securing procedure, thus patients 
sustaining a major complication during the securing procedure, such as massive bleeding, 
major arterial occlusion, large territorial cerebral infarct defined as involving > 1/3 of a 
vascular territory, or new major neurological deficit postprocedure (e.g., hemiplegia or 
aphasia lasting ≥ 12 h post-aneurysm securing) are excluded. Written informed consent is 





At baseline, prior to the aneurysm securing procedure, all patients undergo a CT scan and 
catheter or CT angiography. Additional CT scans are performed 24–48 h after the securing 
procedure, at discharge, 6 weeks after aneurysm rupture, and in cases of worsening 
neurological condition. Additional CT or catheter angiograms are performed after 
endovascular treatment (CONSCIOUS-3 only) to document the completeness of the 
aneurysm occlusion, if symptoms suggestive of cerebral vasospasm or suspicion of cerebral 
infarct occur, and in the case of worsening neurological condition. After study drug initiation, 
neurological assessments using the modified Glasgow Coma Scale (mGCS) and the 
abbreviated National Institutes of Health Stroke Scale (NIHSS) are performed every 6 h until 
Day 14. Patients return to the investigational site for a follow-up visit 6 weeks after SAH. At 
Week 12, specially trained centralized interviewers conduct a structured telephone interview 
to obtain scores for the Glasgow Outcome Scale (extended version, GOSE [19,20]), and 
modified Rankin Scale [21,22]. During this interview, a brief (11-item) standardized 




The primary and secondary endpoints for both studies are summarized in Table 1. The 
primary endpoint is a composite including mortality as well as vasospasm-related cerebral 
infarction, vasospasm-related DIND and vasospasm-related neurological signs and 
symptoms leading to use of a valid rescue therapy. Unlike diseases such as diabetes and 
cancer, where formal guidelines identify appropriate endpoints for assessing safety and 
efficacy [24], there are none for aSAH. The selection of the primary endpoint was based on 
several factors. First, it is similar to that used in the only positive clinical trial of medical 
treatment for aSAH [25]. Second, all of the components are clinically relevant: cerebral 
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infarction is one of the most powerful prognostic factors associated with poor outcome after 
aSAH, DIND is highly associated with cerebral infarction [26,27] and rescue therapy to treat 
DIND is costly. Finally, it is important that the endpoint assesses outcomes that are likely to 
be influenced by a reduction in vasospasm, as this is the mode of action of clazosentan. 
Cerebral infarction and DIND have been associated with vasospasm. For example, 
Weidauer et al [28] reported that 53% of patients experienced new infarcts within 28 days of 
aSAH, and that 81% of these were related to severe cerebral vasospasm. Furthermore, 
approximately 50% of patients with vasospasm will experience DIND [7] and, while 
Dankbaar et al [29] reported that vasospasm does not always cause delayed ischemia, they 
did find that patients with severe vasospasm more often experienced delayed cerebral 
ischemia than those without. The focus on vasospasm-related endpoints is also justified 
because vasospasm is a major preventable cause of poor outcome. There are multiple 
causes of morbidity in patients initially surviving after aSAH, including the initial hemorrhage 
(e.g., extent of bleed), which is not modifiable; surgery-related injury (e.g., retraction or 
perforator injury); and peri-operative morbidity such as hydrocephalus, cardiopulmonary 
complications, metabolic and fluid-related complications which may be managed to a degree 
but cannot always be prevented. 
In CONSCIOUS-2 and CONSCIOUS-3, DIND is defined as a decrease of at least two points 
on the mGCS or an increase of at least two points on the abbreviated NIHSS (Table 2) 
lasting for at least 2 h. For patients who require continuous sedation, when possible sedation 
is interrupted at least once daily to allow for neurological assessment. If a patient is not 
assessable, DIND is defined as administration of a valid rescue therapy for a justifiable 
reason. Rescue therapies include initiation or increase in dose of an intravenous 
vasopressor with or without fluid therapy, or intra-arterial vasodilator or balloon angioplasty. 




The main secondary endpoint is GOSE. GOSE was not the primary endpoint due to 
prohibitively large sample size estimates [30]. Additionally, outcome scales, such as GOSE, 
are not always sensitive to change, particularly when dichotomized (e.g., poor/good 
outcome) [31], and there may be confounders in the interpretation of these scales. For 
example, GOSE uses a categorical scale to assess major social roles (activities of 
independent living, work, leisure, personal relationships) which may be confounded by 
patient age, inter-individual variation in neuroplasticity and recovery capacity, and the degree 
of family and community social support [32]. Moreover, classical outcome scales do not 
address cognitive impairment, which is frequent after aSAH [3]. Together, these factors 
mean GOSE is more appropriate as a secondary rather than primary endpoint.  
Safety endpoints include death up to week 12 post-aSAH; treatment-emergent adverse 
events (including those of special interest, e.g., lung complications, hypotension, anemia, 
cerebral hemorrhage, cardiovascular and eye disorders); adverse events leading to 
premature drug discontinuation; serious adverse events up to 28 days after drug 
discontinuation; new or worsened cerebral infarcts (all etiologies) up to Week 6 post-aSAH; 
and laboratory parameters.  
 
Centralized Critical Events Committee 
In CONSCIOUS-1, investigator assessment of ischemic morbidity led to a different pattern of 
results than a post hoc blinded assessment of the same data by a central review committee 
(Figure 2 [15]). For example, in some cases, investigators attributed DIND to vasospasm 
when central review of angiograms did not show vasospasm. Hypodensities on CT scans 
were sometimes attributed to vasospasm when there was no vasospasm on angiography, or 
when the hypodensities were already present on the CT scan 24 to 48 h after the aneurysm-
securing procedure and were therefore judged centrally to be due to the aneurysm-securing 
procedure or other peri-procedural events. For this reason, CONSCIOUS-2 and 
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CONSCIOUS-3 use a centralized critical events committee comprising neurointensivists, 
neurosurgeons and neuroradiologists to evaluate images and other clinical data from the 
individual centers. Centralized assessment (rather than investigator opinion) has been used 
in many randomized clinical trials to ensure that data are consistent and as closely reflective 
of reality as possible [25]. 
This committee comprises an image review subcommittee of neuroradiologists and a clinical 
review subcommittee of neurosurgeons and neurointensivists. Based on review of CT and 
catheter angiograms, the image review committee determines if angiographic vasospasm is 
present. If a new hypodensity on a CT scan is classified as a cerebral infarction, the 
committee determines its location, volume and etiology. In the absence of an angiogram 
concomitant to a neurological worsening episode, the committee determines the etiology of 
new hypodensities based on best judgment. For instance, a new hypodensity located in a 
large artery or watershed territory would usually be attributed to angiographic vasospasm. In 
contrast, procedure-related infarcts are defined as those appearing within 2 days of surgery, 
in a vascular territory, and attributable to artery occlusion or injury. Hypodensity underlying a 
thick clot, or due to intraparenchymal hemorrhage, an external ventricular drain or small 
hypodensities secondary to retraction injury due to the surgical approach are considered 
encephalomalacia and not infarction. Hypodensity of unknown etiology is considered 
infarction. The clinical review committee is composed of a pool of nine experts (six 
neurosurgeons and three neurointensivists). Each patient is reviewed in an independent 
manner by three reviewers (two neurosurgeons and one neurointensivist) who make a final 
assessment of the individual components of the primary endpoint (cerebral infarction, DIND 
or the administration of rescue therapy and their causes [cerebral vasospasm-related or 
not]). The review is performed through a web-based system giving access to patient clinical 
data as well as study-specific brain images. Unanimity is required. In case of disagreement 
on one or more of the components of the primary endpoint, the initial reviewers discuss the 
case in a consensus meeting. If consensus cannot be reached, the case is adjudicated by 
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an additional reviewer (either the Chair of the committee or an intensivist not among the 
initial reviewers). 
 
Patient management guidelines  
In CONSCIOUS-1, clazosentan use was associated with lung complications (including 
pulmonary edema, acute respiratory distress syndrome, pleural effusion and pneumonia), 
anemia and hypotension. The occurrence of lung complications was associated with positive 
fluid balance. Kramer and Fletcher [33] conducted a meta-analysis of clinical trials of 
endothelin antagonists for aSAH and concluded that they reduce angiographic vasospasm 
and DIND, but on current evidence have no effect on outcome, which is possibly partly 
explained by the increased incidence of hypotension and pulmonary complications. This 
adverse event profile highlighted the importance of careful attention to fluid, and monitoring 
to detect early lung complications and blood pressure changes. CONSCIOUS-2 and 
CONSCIOUS-3 therefore use patient management guidelines to provide a consistent and 
standardized level of care across all study sites. The guidelines are consistent with those 
recommended by the Stroke Council of the American Heart Association [7] and focus on 
maintaining a euvolemic state, avoiding fluid overload, and treating DIND primarily with 
induced hypertension. There are also specific recommendations for prevention, detection 
and management of lung complications, monitoring of rescue therapy, and general patient 
care.  On the basis of these guidelines, CONSCIOUS-3 includes an additional assessment 
of the 15 mg dose, allowing investigators to explore whether there is a greater efficacy/safety 




Statistical considerations and analysis 
The incidence of vasospasm-related morbidity and all-cause mortality in placebo patients 
was initially estimated as 40% and 35% in CONSCIOUS-2 and CONSCIOUS-3, respectively 
based on CONSCIOUS-1 data. The placebo event rate was subsequently amended to 30% 
in CONSCIOUS-2 based on the observed blinded overall (placebo and clazosentan patients 
pooled) event rate in CONSCIOUS-2. The estimation of the placebo event rate in 
CONSCIOUS-3 may be amended and sample size revised in the future based on the real 
observed placebo event rate in CONSCIOUS-2. The sample size estimates of both studies 
were based on a relative risk reduction of 30% for the primary endpoint. The treatment effect 
will be tested by means of logistic regression adjusting for WFNS (I, II, >II). The Wald chi-
square test will be used to determine the treatment effect. The primary analysis will be 
performed on the all-treated patient set. Dichotomous variables will be described using 
incidence and relative risk reduction of the active group(s) relative to placebo, with 
corresponding 95% confidence intervals. GOSE will be categorized into poor outcome (score 
≤ 4) and good outcome (score > 4) and analyzed using the same statistical methods as for 
the primary endpoint. In both studies, the association between GOSE (dichotomized) and 
categorized total infarct volume, presence or absence of new cerebral infarcts due to 
vasospasm, as well as GOSE (dichotomized) and DIND (presence, absence) will be 
explored by means of chi-square statistics. Comparability of baseline demographics within 
each study will be considered on the basis of descriptive statistics, with relevant past or 
present concomitant diseases coded using MedDRATM.  
 
Conclusion 
New strategies for vasospasm prevention are needed to improve outcome after aSAH. 
CONSCIOUS-2 and CONSCIOUS-3 are large, multinational studies to investigate the 
efficacy and safety of clazosentan, an endothelin receptor antagonist, in the prevention of 
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vasospasm-related adverse outcome after aSAH. The designs of these studies were based 
on experience from CONSCIOUS-1 (Table 3). When designing these studies, key 
considerations were: selection of primary endpoint; drug dose; possible differences in 
incidence of angiographic vasospasm in patients undergoing clipping or coiling; minimizing 
inclusion of patients unlikely to benefit from drug treatment; assessment of the radiology and 
clinical endpoints; and avoiding medical complications of treatment. These studies recruit a 
well defined population enriched for risk of vasospasm and use a centralized critical events 
committee to ensure consistency in data interpretation. It is hoped that these trials will 
facilitate a move towards more uniform and evidence-based management after aSAH.  
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Table 1. Study endpoints  
Primary endpoint Secondary endpoints  
Composite endpoint of at least one of: 
• Death (any cause) 
• New cerebral infarct(s) due to cerebral 
vasospasm as either the primary or 
relevant contributing cause, or not 
adjudicated to be entirely due to causes 
other than vasospasm 
• Delayed ischemic neurological deficit due 
to cerebral vasospasm as either the 
primary or relevant contributing cause, or 
not adjudicated to be entirely due to 
causes other than vasospasm  
• Neurological signs or symptoms 
(depending on state of consciousness) in 
the presence of confirmed cerebral 
vasospasm on angiography (digital 
subtraction angiography [DSA] or 
computerized tomography angiography 
[CTA]) leading to the administration of a 
valid rescue therapy 
• Functional outcome using the Glasgow 
Outcome Scale (extended version, 
dichotomized into good (> 4) or poor (≤ 4) 
at Week 12 
• Total volume of new cerebral infarcts of all 
etiologies at Week 6 post-hemorrhage 
• Occurrence of death and the individual 







Table 2. mGCS and abbreviated NIHSS (as used in DIND assessment) 
mGCS abbreviated NIHSS 
Test Response options  Test Response options 
Eye 
Opening  
1. No response 
2. Response to pain 
3. Response to voice 
4. Spontaneous response 
Facial 
Palsy 
0. Normal symmetrical 
movement  
1. Minor paralysis 
2. Partial paralysis 
3. Complete paralysis  
(one or both sides) 
Verbal 
Response 
1. No response 
2. Incomprehensible words 





0. No drift 
1. Drift 
2. Some effort against gravity 
3. No effort against gravity 
4. No movement 
9. Amputation, joint fusion 
5a. Left arm 




Right arm  
 
1. No response 
2. Abnormal extension 
3. Abnormal flexion 
4. Withdrawal 
5. Localizes 
6. Follows commands 
Motor 
Leg 
0. No drift 
1. Drift 
2. Some effort against gravity 
3. No effort against gravity 
4. No movement 
9. Amputation, joint fusion 
6a. Left leg 
6b. Right leg 
The modified score = eye opening response Total score = facial palsy + left arm + right 
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+ verbal response + worst motor response  arm + left leg + right leg  
DIND: delayed ischemic neurological deficit; mGCS: modified Glasgow Coma Scale; NIHSS: 




Table 3. Comparison of key features of the CONSCIOUS studies  
 CONSCIOUS-1  CONSCIOUS-2  CONSCIOUS-3  
N 413 1157 >1400 
Securing procedure  Clip or coil  Clip  Coil  
Clot type (from CT 
scan) 
 local thin 
 diffuse thin 
 local thick 



























No* Yes  Yes  
Patient management 
guidelines  
No  Yes  Yes  



















*Central radiology review was performed (CT scans and angiograms). CT: computed 
tomography; GOSE: Glasgow Outcome Scale. 
Figure 1: Study design. aSAH: aneurysmal subarachnoid hemorrhage; CT: computed 
tomography; GOSE: Glasgow Outcome Scale (extended); mRS: modified Rankin scale; 








Figure 2: Endpoint data from CONSCIOUS-1 (all-treated set) as assessed by 
investigators (grey boxes) compared with central assessment (black boxes). A, 
Occurrence of moderate to severe angiographic vasospasm; B, Composite endpoint; 
C–E, Individual morbidity elements of the composite endpoint. All morbidity and 
mortality endpoints are within 6 weeks of aneurysm rupture. DIND: delayed ischemic 
neurological deficit.  
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